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doi:10.1016/j.ejvs.2010.02.019Abstract Objective: This study aimed to test a percutaneous technique for aneurysm-sac
filling by means of in situ polymerisation in an in vivo model.
Design: Aortic Customize is a new endovascular treatment concept for aortic aneurysms:
a non-cross-linked liquid elastomer is injected to fill the aneurysm sac around a balloon-
catheter. With this method, a compliant elastomer mould with a patent lumen is created.
Material: The formulation used in the experiments consisted of a two-component addition-
cure liquid-silicone formulation, based on vinyl-terminated polydimethylsiloxane (PDMS).
Methods: The concept of aneurysm-sac filling was tested in vivo in porcine experiments (nZ 3).
Results: In vivo porcine experiments with the sac-filling application showed successful exclusion
of the created aneurysms with patent lumens and absence of endoleaks. The aneurysms were
excluded successfully in the in vivo model, injecting elastomer through a 7-French catheter,
filling up the entire aneurysm sac.
Conclusions: These in vivo experiments demonstrate that the principle of aneurysm-sac filling by
means of in situ curing is feasible, excluding the aneurysm and creating a new lumen. Further
long-term animal experiments must be done prior to consideration of clinical application.
ª 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.526 6750.
lumc.nl (W.M.P.F. Bosman).
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Figure 1 Aortic Customize, the treatment concept: (A) A
schematic drawing of an abdominal aortic aneurysm, (B) A fill
catheter is inserted through a femoral artery, (C) An endo-
vascular balloon excludes the aneurysm from the circulation,
(D) The two components of the elastomer are pumped in the
excluded aneurysm. Excess blood is pushed out alongside the
balloon, (E) After the aneurysm is filled, the elastomer takes 5
min to cure, (F) When the elastomer has cured, the endovas-
cular balloon is deflated, leaving the aneurysm excluded with
a new lumen.
66 W.M.P.F. Bosman et al.Endovascular repair of aortic aneurysms has evolved into
a widely used technique. Large multicentre studies have
shown clear advantages of this less invasive technique over
conventional open repair.1,2 However, with the more
widespread use, disadvantages have also become more
evident. Complications and re-interventions caused mainly
by endoleaks, endotension, stent-graft migration and
device failure are of major concern.3,4 Due to anatomical
restrictions, endovascular aneurysm repair (EVAR) is not
available for each patient with an abdominal aortic aneu-
rysm (AAA). Manufacturers of commercially available EVAR-
grafts state that an infra-renal aneurysm neck of at least
15 mm is needed to ensure a strong proximal seal, and
tortuous anatomy is a (relative) contraindication. A study
from Timaran et al. has shown that, with 27% of AAAs, the
anatomy of the aneurysm makes it unsuitable for EVAR
because of insufficient neck length, large neck diameter or
severe angulation.5 These problems are less manifest with
fenestrated or branched EVAR-grafts, although the use of
these grafts is not always possible.
Often, arterial cut-down of the femoral arteries is
necessary, as bulky delivery devices with an external diam-
eter of 12e16 French (Fr) have difficulties passing the stent
through arteriosclerotic, stenotic and, often, elongated iliac
vessels. The inguinal incisions can cause seroma, haematoma
or wound infection, adding morbidity to the procedure.6,7
To overcome these disadvantages, Aortic Customize was
devised: a method of excluding the aortic aneurysm using
endovascular techniques to inject a biocompatible elas-
tomer into the aneurysm sac (Fig. 1). The non-cross-linked
liquid elastomer is used to fill the aneurysm sac around
a balloon-catheter. An endoluminal mould fills up the
aneurysm sac after in situ polymerisation. With this
method, an elastomer cuff with a patent lumen is created.
An earlier study in an in vitro circulation model by our
group has shown that filling an aneurysm sac with an inject-
able biocompatible elastomer brings about a reduction in the
wall stress.8 With this reduction in wall stress, a reduction in
rupture risk is achieved, since aneurysm rupture occurswhen
the local wall stress exceeds the local wall strength.9,10
This study aimed to test the treatment concept of
aneurysm-sac filling in an in vivo porcine model.
Materials and methods
The elastomer
The formulation used in the experiments consisted of
a two-component room-temperature addition-cure liquid-
silicone formulation, obtained from Viazym BV (ViaZym BV;
Delft, the Netherlands). The two components consist of:
 A platinum containing vinyl-terminated poly-
dimethylsiloxane (PDMS) with an optimised molecular
weight with regard to viscosity versus mechanical
properties of the cured end-product (elongation to
break, modulus). This component further contains
surface-treated amorphous silica and a sesquisiloxane-
like material known as Vinyl Q, which is known to
increase tear-strength of the final cured elastomer
without much increase in viscosity A methylhydro-dimethyl-siloxane co-polymer contain-
ing vinyl-terminated PDMS. This component further
contains surface-treated amorphous silica and Vinyl Q.
Silicone-based elastomers meet the requirements of
blood compatibility and have been successfully used in
intra-vascular applications by others.11e16 The material is
non-toxic and cross-links isothermically in the presence of
blood, without the release of toxic by-products. The
viscosity of the compound allowed infusion rates of up to
2 mL s1 using a standard angiographic pump with an
injection pressure of up to 1200 pounds per square inch.
The substance has an average polymerisation time of
w5 min. After curing, the material had a yield-stress of
w400 kiloPascal (kPa), failing at >20% elongation. The
density of the cured elastomer is 1.0167 g cm3.
A cast of the material with the added cross-linker and
filler has been subjected to fatigue tests at 21 cycles s1
with stresses comparable to the stresses in the human aorta.
No signs of material failure or tear have been observed after
1 month, which is comparable to an exposure of 18 years in
a circulation with a mean frequency of 70 beats min1.
In vivo porcine experiment
After selection of the ideal composition of the elastomer,
the concept of sac filling through a small-calibre catheter
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shown the feasibility of the treatment concept in a dynamic
in vitro set-up.8
To investigate the in vivo feasibility of the treatment
concept, three in vivo porcine experiments were conducted.
The animal experiment has been approved by the animal
ethical committee of the Maastricht University Medical
Centre. Three separate aneurysms were created by stitching
ellipse-formed polyester patches in longitudinal incisions in
polyester-tube grafts. The aneurysms were 75-mm long and
had aneck and sacdiameter of 8mmand25mm, respectively.
In the adult pigs (weight range: 45e55 kg), general anaes-
thesia was induced and, following this, the abdomen was
prepared in a sterile manner and opened through a midline
incision. The aorta was exposed from the renal arteries to the
trifurcation. Heparin was not administered. Non-traumatic
vascular clamps were used to clamp the aorta below the
renal arteries and above the trifurcation. The aorta was
transected and a 7-cm segment was excised. The polyester
aneurysm was sewn end-to-end into the defect with 4/
0 running prolene sutures (Ethicon, Somerville, NJ, USA)
(Fig. 2A and B). Circulation was restored and haemostasis was
achieved. The abdomen was not closed, allowing direct
observation of the treatment concept (Fig. 2D). Following
this, bilateral incisionsweremade in thegroinand the femoral
arteries were exposed. Through an arteriotomy in the leftFigure 2 The porcine experiments: a porcine aorta was ligated (
placing the aneurysm, a fill catheter and an endovascular balloon
The aneurysm sac was excluded from the circulation by pumping up
an angiographic pump (D), which was attached to the 7 Fr fill cathe
which cured in less then 5 min (E). After the successful exclusion
harvested (F). From the polyester aneurysm sac a perfect elastome
the endovascular balloon (H).femoral artery, a 7-Fr catheter (Boston Scientific,Natick,USA)
was placed in the aneurysm sac and a control angiogram was
made with standard radiographic contrast (Omnipaque, GE
Healthcare, Fairfield, USA), showing no leakages from the sac
or the attachment sites. Through the contralateral femoral
artery, a 7-Fr catheter with an 8  100 mm endovascular
balloon (Cordis Corporation, New Brunswick, USA) was inser-
ted and placed in the aneurysm, just below the renal arteries.
The balloon was inflated with a mixture of saline solution and
radiographic contrast (Omnipaque, GE Healthcare, Fairfield,
USA), thereby excluding the aneurysm from the circulation.
A standard angiographic pump, containing a cassette with the
elastomer, was connected to the catheter in the left femoral
artery (Fig. 2C). The excluded aneurysm was filled with the
elastomer, replacing the contrast in the aneurysm. The
aneurysms were filled with6.1 mL of elastomer [Z(volume
aneurysm sac volume of the balloon)þ 5%]. The elastomer
was given 5 min to cure, after which the balloon was deflated
and circulation was restored. We considered the treatment
successful if the sac was excluded from the circulation, while
the peripheral arteries were still perfused. Control angio-
grams were carried out to see that the aneurysms were
treated successfully and were free from contrast. After the
experiments, the pigs were observed for 30 min, following
which they were sacrificed and the aneurysms were retrieved
and inspected.A) and replaced by a hand made polyester aneurysm (B). After
were inserted through an entrance in the femoral arteries (C),
the endovascular balloon. The two components were loaded in
ter. The excluded aneurysm sac was filled with the elastomer,
the specimen was terminated and the excluded aneurysm was
r mould was harvested (G), with a patent lumen at the place of
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The polyester aneurysms were inserted successfully in the
porcine aortae (Fig. 2A and B). Pre-treatment angiograms
showed no leakages from the aneurysm (Fig. 3) or its anasta-
moses. The aneurysms were successfully excluded from the
circulation with the balloon, after which the sacs were filled
with the elastomer through the 7-Fr catheter (Figs. 2 and 3).
After 5 min, the elastomer had cured and the balloon
was deflated, leaving a patent lumen. Control angiograms
showed a straight, patent lumen. The aneurysm sac was
excluded as there was no contrast or palpable pulsations in
the former aneurysm sac. Pulsations, however, were
present in the pigs’ hind legs.
Dissection of the aneurysms, after euthanisation of the
animals, showed that the sac was completely filled by the
elastomer, with a patent lumen at the site of the balloon
(Fig. 2EeH).
Discussion
The concept of filling the sac of an abdominal aneurysm with
abiocompatibleelastomer is anewtreatmentoption, offering
several advantages over conventional and endovascular
techniques. These in vivo experiments show that it is feasibleFigure 3 Angiographic recordings of the porcine experiment. Ad
polyester aneurysm (A). After placing a 7 Fr fill catheter, the aneu
balloon. Through the 7 Fr catheter (arrow), the viscose elastome
contrast (dotted arrows) (B), When the aneurysm sac was entirely fi
deflated and extracted (C), Control angiography showed an exclude
or elastomer embolisms were detected.to achieve complete exclusion of the aneurysm with our new
technique, using only a 7-Fr catheter and sheath.
In a recent in vitro study, Barnett et al. also described
a treatment concept in which the aneurysm sac is filled
with a liquid polymer.17 In their in vitro study, they use
hydrogels such as EmboGel and UltraGel to fill the aneu-
rysm sac around an endovascular stent. EmboGel is
a mixture of iohexol and alginate, while UltraGel consists of
Irgacure, iohexol and polyethylene glycol diacrylate. In the
search for a polymer solution for aneurysm-sac filling, we
considered the use of alginates and acrylates. However,
these substances did not meet our specifications with
regard to durability; both materials are applied in the form
of a biodegradable hydrogel,18,19 which is undesirable as
the implant is expected to stay in place for many years. In
addition to the unfavourable bio-stability of the hydrogel-
based solutions, these materials possess insufficient
inherent strength and, therefore, need an additional
endovascular stent to stabilise the aneurysm wall when
used as sac-filling. This will still necessitates a bulky device
in order to insert the graft in the aneurysm sac, thereby
losing the advantage of a percutaneous approach.
Low elastic modulus of the implant, preferably matching
that of a healthy aorta (1.18  0.21 MPa),20 is only possible
with a small number of elastomers, PDMS being among the
most versatile, the most biocompatible, non-biodegradableding contrast to the circulation shows the successfully inserted
rysm was excluded by an B 8 mm contrast filled endovascular
r was pumped in the aneurysm sac, pushing away the present
lled and the elastomer had cured, the endovascular balloon was
d aneurysm sac with a patent straight lumen (D), No endoleaks
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applications.11e16
Benefits of new technique
Although the results are quite preliminary, the concept of
aneurysm-sac filling has a number of hypothetical advan-
tages compared to the current EVAR-techniques. The major
complication of EVAR is endoleak after the placement of
the EVAR graft. We expect that the sac-filling technique is
free of type II endoleaks (branch-vessel leakage) because,
similar to the aneurysm sac, branch-vessels will be
occluded by the elastomer. Type III endoleaks are not likely
to occur as the mould is cast in one piece and there is no
graft material in which tears can occur. As the material is
non-porous, type IV endoleak is not likely to occur.
With the current generation of EVAR-grafts, angulation
of the AAA neck is an important excluding factor for
treatment. When endovascular balloons will be available in
different kinds of form and configuration, in theory, any
AAA with a deviant anatomy will become treatable. With
current EVAR-techniques, severe angulation may lead to
endoleaks21e23 and to kinking of the graft material and
eventually to migration of the graft.23e25 The fluidity of the
non-polymerised elastomer inherently causes adjustment
to the geometry of the aneurysm, not only by filling the
large aneurysm sac but also by diffusing into all irregulari-
ties and side-holes. The elastomer mould will fixate itself as
it customizes itself to the form of the AAA sac.
Another important exclusion criterion for the current
EVAR therapy is strong tortuosity or occlusive disease of the
iliac arteries. Many stent-grafts need a minimal diameter of
12e16 Fr for access of the bulky delivery sheath. To fill the
sac with the biocompatible elastomer, a fill catheter with
minimal diameter of 7 Fr needs to be introduced into the
aneurysm sac through the femoral or brachial artery.
In addition to the treatment concept as depicted in
Fig. 1, the elastomer and injection-technique are more
broadly applicable. The elastomer can already be used as
an adjuvant with current stent-grafts when problems of
endoleak or migration occur. In these cases, the elastomer
can be used to fill-up the aneurysm sac and secure the
endovascular stent-graft.26
Potential limitations of technique
Despite the potential benefits, the treatment option might
have other shortcomings. Although we did not observe this in
our in vivo and in vitro experiments, type I endoleaks may
still occur at the junction-sites of the elastomer mould and
the native vessel-wall. However, the addition of conven-
tional stents might still be an option to repair this.
Furthermore, it is not desirable to have leakage of the fluid
elastomer (before the cross-linking) to the peripheral vessels
(e.g., renal arteries), as this might act as an arterial
embolus. During the filling procedure, the aneurysm sac is
excluded from the circulation, below the renal arteries. In
the various in vitro and in vivo experiments we conducted,
there was no visible sign of leakage of the elastomer to distal
areas, along the side of the balloon.8 However, it could still
be possible that small invisible fragments, indeed, leakedaway. Intensive in vivo animal experiments will have to be
done to exclude this potential disadvantage. The amount of
elastomer which has to be used can be calculated from
preoperative computerised tomography (CT) scan volume
measurements, thereby preventing potential ‘overfilling’ of
the sac, which may lead to leakage.
Another theoretical disadvantage is that, during the filling
of thesac, thepressuremay increase in suchawaythat theAAA
sac is at risk of rupture. If, indeed, such a rupture does occur, it
will inall probabilitybesealeddirectlybythecuringelastomer.
The potential rupture might then not be relevant anymore, as
it is directly treated and excluded from the circulation.
Animal experiments are necessary to prove the long-
term success of the treatment concept. At this moment, we
do not yet know how the aneurysm sac will react to the
elastomer filling in vivo. It is not clear if the sac will
continue to dilate after elastomer filling or that the present
thrombus will break down, creating new open spaces in the
aneurysm sac. Experimenters will have to investigate
whether this might lead to clinically relevant problems.
All these hypothetical benefits and potential shortcom-
ings will have to be investigated before clinical application
can be considered.
Perspective
In earlier in vitro research, we have shown that filling the
aneurysm sac with elastomer clearly decreases the amount
of wall stress. In a circulation model, a latex aneurysm was
successfully treated with elastomer, reducing the wall stress
from 15.6 N cm2 before sac-filling to 1.1 N cm2after sac-
filling.8
Prior to its clinical application, the focus will have to be
on the long-term results of the aneurysm exclusion and on
the development of new endovascular balloons. For
example, to treat aneurysms of all different morphologies,
it will be necessary to be able to place kissing balloons with
a perfect seal between each other.
Following these successful in vivo experiments, we will
conduct further animal and in vitro experiments, testing
this novel treatment concept, eventually leading to its
clinical use in treating aortic aneurysms.
Conclusion
The technique of aortic customizing offers a whole new
approach to treating aneurysmatic disease of the abdominal
aorta. Advantages are the percutaneous approach, absence
of (types IIeIV) endoleaks and impossibility of kinking or
migration of the graft. Therefore, it circumvents most major
problems associated with currently available stent-grafts.
This in vivo study shows that treatment concept is feasible
and it potentially offers a custom-made treatment for the
majority of arterial aneurysms. However, clinical application
of this sac-filling technique is still an unproven modality and
long-term animal research needs to be done.
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